John R Bergquist1, Ryan T Groeschl2, Tommy Ivanics2, Christopher R Shubert1, Elizabeth B Habermann3, Michael L Kendrick2, Michael B Farnell2, David M Nagorney2, Mark J Truty2, Rory L Smoot4. 1. Section of Hepatobiliary and Pancreatic Surgery, Division of Subspecialty General Surgery, Department of Surgery, Mayo Clinic, Rochester, USA; Surgical Outcomes Program, Robert D and Patricia E Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA. 2. Section of Hepatobiliary and Pancreatic Surgery, Division of Subspecialty General Surgery, Department of Surgery, Mayo Clinic, Rochester, USA. 3. Surgical Outcomes Program, Robert D and Patricia E Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA. 4. Section of Hepatobiliary and Pancreatic Surgery, Division of Subspecialty General Surgery, Department of Surgery, Mayo Clinic, Rochester, USA. Electronic address: Smoot.Rory@mayo.edu.
Abstract
BACKGROUND: Intrahepatic lesions of mixed hepatocellular (HCC) and intrahepatic cholangiocellular carcinoma (ICC) histology are rare. The aim was to describe the natural history of these tumors relative to monomorphic ICC or HCC utilizing the National Cancer Data Base (NCDB). METHODS: Patients with ICC, HCC, and mixed histology (cHCC-CCA) were identified in the NCDB (2004-2012). Inter-group comparisons were made. Kaplan-Meier and multivariable Cox Proportional Hazards analyzed overall survival. RESULTS: The query identified 90,499 patients with HCC; 14,463 with ICC; and 1141 with cHCC-CCA histology. Patients with cHCC-CCA histology were relatively young (61 vs. 62 (HCC, p = 0.877) and 67 (ICC, p < 0.001) years) and more likely to have poorly differentiated tumor (29.2% vs. 10.3% (HCC) and 17.2% (ICC) p < 0.001). Median overall survival for cHCC-CCA was 7.9 months vs. 10.8 (HCC) and 8.2 (ICC, all p < 0.001). Stage-specific survival for mixed histology tumors was most similar to that of HCC for all stages. cHCC-CCA were transplanted at a relatively high rate, and transplant outcomes for mixed tumors were substantially worse than for HCC lesions. DISCUSSION: cHCC-CCA demonstrate stage-specific survival similar to HCC, but post-surgical survival more consistent with ICC. Patients with a pre-operative diagnosis of cHCC-CCA should undergo resection when appropriate.
BACKGROUND:Intrahepatic lesions of mixed hepatocellular (HCC) and intrahepatic cholangiocellular carcinoma (ICC) histology are rare. The aim was to describe the natural history of these tumors relative to monomorphic ICC or HCC utilizing the National Cancer Data Base (NCDB). METHODS:Patients with ICC, HCC, and mixed histology (cHCC-CCA) were identified in the NCDB (2004-2012). Inter-group comparisons were made. Kaplan-Meier and multivariable Cox Proportional Hazards analyzed overall survival. RESULTS: The query identified 90,499 patients with HCC; 14,463 with ICC; and 1141 with cHCC-CCA histology. Patients with cHCC-CCA histology were relatively young (61 vs. 62 (HCC, p = 0.877) and 67 (ICC, p < 0.001) years) and more likely to have poorly differentiated tumor (29.2% vs. 10.3% (HCC) and 17.2% (ICC) p < 0.001). Median overall survival for cHCC-CCA was 7.9 months vs. 10.8 (HCC) and 8.2 (ICC, all p < 0.001). Stage-specific survival for mixed histology tumors was most similar to that of HCC for all stages. cHCC-CCA were transplanted at a relatively high rate, and transplant outcomes for mixed tumors were substantially worse than for HCC lesions. DISCUSSION: cHCC-CCA demonstrate stage-specific survival similar to HCC, but post-surgical survival more consistent with ICC. Patients with a pre-operative diagnosis of cHCC-CCA should undergo resection when appropriate.
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: M Shimoda; D G Farmer; S D Colquhoun; M Rosove; R M Ghobrial; H Yersiz; P Chen; R W Busuttil Journal: Liver Transpl Date: 2001-12 Impact factor: 5.799
Authors: C Panjala; D L Senecal; M D Bridges; G P Kim; R E Nakhleh; J H H Nguyen; D M Harnois Journal: Am J Transplant Date: 2010-05 Impact factor: 8.086
Authors: Jordi Rimola; Alejandro Forner; Maria Reig; Ramon Vilana; Carlos Rodríguez de Lope; Carmen Ayuso; Jordi Bruix Journal: Hepatology Date: 2009-09 Impact factor: 17.425
Authors: Valery Vilchez; Malay B Shah; Michael F Daily; Luis Pena; Ching-Wei D Tzeng; Daniel Davenport; Peter J Hosein; Roberto Gedaly; Erin Maynard Journal: HPB (Oxford) Date: 2016-01-07 Impact factor: 3.647
Authors: Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler Journal: Abdom Radiol (NY) Date: 2019-06
Authors: Leigh Anne Dageforde; Neeta Vachharajani; Parissa Tabrizian; Vatche Agopian; Karim Halazun; Erin Maynard; Kristopher Croome; David Nagorney; Johnny C Hong; David Lee; Cristina Ferrone; Erin Baker; William Jarnagin; Alan Hemming; Gabriel Schnickel; Shoko Kimura; Ronald Busuttil; Jessica Lindemann; Sander Florman; Matthew L Holzner; Rami Srouji; Marc Najjar; Lavanya Yohanathan; Jane Cheng; Hiral Amin; Charles A Rickert; Ju Dong Yang; Joohyun Kim; Jennifer Pasko; William C Chapman; Maria B Majella Doyle Journal: J Am Coll Surg Date: 2020-12-13 Impact factor: 6.113